Development and Preclinical Evaluation of [<sup>211</sup>At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer-Reference-Cited by-同舟云学术

Development and Preclinical Evaluation of [²¹¹At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer

Published:2024-02-29 Issue:4 Volume:65 Page:593-599
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

El Fakiri Mohamed,Ayada Nawal,Müller Marius,Hvass Lars,Gamzov Teodor H.,Clausen Anne Skovsbo,Geis Nicolas M.,Steinacker Nils,Hansson Ellinor,Lindegren Sture,Aneheim Emma,Jensen Holger,Eder Ann-Christin,Jensen Andreas I.,Poulie Christian B.M.,Kjaer Andreas,Eder Matthias,Herth Matthias M.

Publisher

Society of Nuclear Medicine

Reference38 articles.

1. Cancer today. International Agency for Research, World Health Organization website. https://gco.iarc.fr/today/home. Updated 2020. Accessed September 30, 2023.

2. Overall survival and second primary malignancies in men with metastatic prostate cancer

3. Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis;He;Medicine (Baltimore).,2020

4. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer;Fallah;Clin Cancer Res.,2023

5. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid Electrophilic ²¹¹At‐Astatination of Trimethylgermyl Arenes;ChemPlusChem;2024-09-05

2. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

3. In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure;EJNMMI Radiopharmacy and Chemistry;2024-06-17